In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Chronic Spontaneous Urticaria
Continuing Medical Education
All News
Advertisement
The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.
Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.
A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.
Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
4
Improving Early Identification and Escalation of HS
5